Patients with chronic (CM) and high frequency episodic migraine (HFEM) report cognitive complaints that contribute to migraine burden. Although, there is little evidence about the ef-fects of migraine treatments on these symptoms. Objective: To evaluate the effect of preventive treatment on the impact of cognitive symptoms, specifically the ability to concentrate, in individuals with CM and HFEM. Methods: Prospective cohort study in patients with CM and HFEM initiating treatment with botulinum toxin (BT) or anti-CGRP/R monoclonal antibodies (mAbs). Patients were evaluated at baseline and after 3 months of treatment, using a headache diary and a question about the im-pact of migraine attacks on concentration (never, rarely, sometimes, often, and always). Results: 108 patients (105 females, 44.3 years of age on average), 75% with CM and 27% with HFEM were included, 55 received a first session of BT and 53 received 3 injections of a monthly mAb. In both groups, there was a significant decline on the impact of migraine in concentration (related samples Wilcoxon signed rank test <0.001) compared to baseline. Reduction in monthly headache days was the main predictor of any concentration improvement, while treatment group, age, ongoing medication with topiramate or baseline medication overuse were not sig-nificant. Conclusion: Preventive treatment of HFEM or CM with drugs not acting on central nervous sys-tem is associated with a decrease of the impact of migraine attacks on concentration, predicted by the decline in headache days. These results indicate that migraine preventive treatment also improves non-pain symptoms, which is relevant given the contribution of cognitive complaints to the impact of headache attacks
29 November 2024 in Clinical Neurology and Neurosurgery
Migraine is a cyclic condition with attacks consisting mainly of intense headaches, sensory intolerance, and nausea or vomiting. Loss of consciousness during attacks is often attributed exclusively to a neurally mediated reflex to pain, although it may also be due to migraine’s autonomic impairment, with cardiac conduction abnormalities, probably in relation to a degree of reduced sympathetic function. We report the case of a 51-year-old woman presenting episodes of syncope exclusively after vomiting during migraine attacks. A 24-hour Holter monitoring performed during a migraine attack disclosed an intermittent complete atrioventricular block coincident with an episode of syncope. The patient was implanted with a pacemaker without further syncopes on subsequent attacks. This case highlights the importance of clinical suspicion and investigation of syncope during migraine attacks. Recurrent syncope during migraine should not be attributed to pain to avoid misdiagnosis and ensure the treatment of other important causes of syncope.
4 December 2025 in Portuguese Journal of Public Health
Background: The COVID-19 pandemic and its consequent confinement have caused a major impact on people living with dementia (PLD). We aimed to ascertain the use of antipsychotic medication in this population due to behavioural symptoms during confinement. Methods: We conducted a retrospective study evaluating clinical registrations, namely the use of psychoactive medication, of PLD followed regularly in a Portuguese dementia outpatient clinic during two different confinement periods. Results: A total of 101 patients were included. Alzheimer’s disease was the most frequent diagnosis, most of them in moderate/severe stage. Antipsychotics were used in 21.7% of patients. During confinement, a residual number of patients needed antipsychotic dose increase. Conclusion: Confinement due to COVID-19 in this population was not associated with a significant increase of antipsychotics use. We hope our work may help clarify issues related to the need for antipsychotic medication in behavioural symptoms during confinement in PLD.
28 October 2026 in Headache: The Journal of Head and Face Pain